The commitment to improve lives starts at the top.

Robert E. Dudley, Ph.D.

Chairman, Chief Executive Officer and President

Robert E. Dudley, Ph.D., has devoted his career to developing products that revolutionize healthcare for men. As the co-inventor of multiple formulations of testosterone replacement therapies, he is a leading voice in hypogonadism and men’s health.

Driven by a mission to help men overcome the symptoms of hypogonadism, Dr. Dudley established Clarus Therapeutics, Inc. in 2004 and has served as Chief Executive Officer, President and Chairman of the Board of Directors since its founding. Prior to founding Clarus Therapeutics, Dr. Dudley served as the President, Chief Executive Officer and Director of Anagen Therapeutics. He also held senior executive positions at Unimed Pharmaceuticals, including President and CEO. Dr. Dudley has more than 30 years of experience in the testosterone replacement therapy field. Most notably, he led the discovery, development, regulatory approval and launch of AndroGel 1%, the first testosterone gel product, which became the market leader.

Patients deserve a choice and an opportunity to have access to medicines that can improve the quality of their lives.

Ric Peterson

Chief Financial Officer

Ric Peterson has deep financial expertise and forward-thinking business leadership, with extensive experience in capital markets having completed numerous successful private and public financings (IPOs). He joined Clarus Therapeutics in February 2021 as Chief Financial Officer, bringing 25 years of experience in the pharmaceutical industry and long-standing relationships within the financial community. Prior to joining Clarus Therapeutics, Mr. Peterson served as Chief Financial Officer for several clinical-stage biopharmaceutical companies, including Sienna Biopharmaceuticals, Dermavant Sciences, Inc. and Novan, Inc. He was also Chief Financial Officer of Medicis Pharmaceutical Corporation, a commercial pharmaceutical company.

It’s an exciting time to join the Clarus team and help them grow Clarus into a profitable, multi-product pharmaceutical company.

Steven A. Bourne

Chief Administrative Officer

Steve Bourne has a passion for working with innovative, early-stage life sciences companies. He joined Clarus Therapeutics in February 2004 and currently serves as Chief Administrative Officer. His career has spanned more than three decades, amassing deep administration and financial leadership expertise for specialty pharmaceutical, biotech and medical device companies. Prior to joining Clarus Therapeutics, Mr. Bourne served as Chief Financial Officer, Secretary and Treasurer at Anagen Therapeutics and Treasurer, Secretary and Controller at Aksys, a publicly traded medical device company.

For me, it’s personal. Working in men’s health is gratifying for me but I also do it for my family and my loved ones.

Frank Jaeger

Chief Commercial Officer

Mr. Jaeger joined Clarus Therapeutics in 2019 as Chief Commercial Officer with over 20 years of progressively increasing responsibility in the biopharmaceutical industry. With significant pre-launch, launch, and in-market experience, Mr. Jaeger is committed to ensuring that innovative treatments are developed and promoted through the lens of the customer. His broad leadership and management experience spans across R&D, Medical Affairs, Business Development, and most notably throughout Commercial Operations. Prior to joining Clarus, he spent over 10 years at Abbott/AbbVie and was responsible for the Men’s Health division growing it from $600 MM to over $1.3 BN. Previously, Mr. Jaeger was at Solvay Pharmaceuticals in roles of increasing responsibility within the Neuroscience, Gastroenterology, and Women’s Health franchises. Mr. Jaeger received a B.A. and M.A. in clinical psychology from University of Illinois, Chicago and an M.B.A. from Lake Forest Graduate School of Management.

It’s really been rewarding to see men suddenly having conversations with their physicians and realizing that they can be helped.

It’s really been rewarding to see men suddenly having conversations with their physicians and realizing that they can be helped.

Jay Newmark, MD

Chief Medical Officer

With extensive experience in both private urology practice and commercial product development, Jay Newmark was already a leading voice in men’s health when he joined Clarus Therapeutics in December 2019 as Chief Medical Officer. Following 16 years as a urologist in private practice, he worked to develop advanced detection technologies for prostate cancer as Senior Director of Medical Affairs at Genomic Health and OPKO Health. He has worked closely with clinical development organizations and academic researchers to design clinical trial protocols and co-author publications on topics in oncology and urology.

It’s fulfilling to be part of an organization committed to developing innovative treatments that make a real difference.

Steven A. Bourne, CPA

Chief Financial Officer, Secretary and Treasurer

Steven A. Bourne, CPA, is a finance and accounting professional with a passion for working with innovative, early-stage life science companies. He joined Clarus Therapeutics in February 2004 and currently serves as Chief Financial Officer, Secretary and Treasurer. His career has spanned more than two and a half decades, amassing deep financial leadership expertise for specialty pharmaceutical, biotech and medical device companies. Prior to Clarus Therapeutics, he served as Chief Financial Officer, Secretary and Treasurer at Anagen Therapeutics and Treasurer, Secretary and Controller at Aksys, a public medical device company.

For me, it’s personal. I do this not only for myself, but for my family and my loved ones.

Rozita Passarella

Vice President, Marketing

Rozita Passarella has over a decade of experience as a sales and marketing leader in biopharmaceuticals. Before joining Clarus, she was instrumental in helping AndroGel gain blockbuster status during her tenure. Ms. Passarella has broad-based experience in a variety of disease states, including cardiology, immunology, metabolic, and women’s health. She has led marketing efforts to launch new formulations as well as new products within large integrated delivery networks (IDNs) and group practices.

Clarus is focused and relentless in improving patients’ lives by addressing unmet needs, whether that be in delivering a new mode of administration or a therapy for an orphan condition that is without treatment or therapy.

LaTonya Wright

Vice President, Sales

LaTonya Wright is a proven leader whose teams consistently exceed ambitious sales targets. She joined Clarus Therapeutics in October 2019 as Vice President, Sales with more than 20 years of healthcare experience gained through roles at Amgen, Abbott and AbbVie. Under her leadership as Regional Sales Director at AbbVie, her team won national awards for sales and performance. Previously, she launched another TRT treatment with an innovative go-to-market model. At Clarus Therapeutics, Ms. Wright is in charge of building and leading the sales organization by developing sales, market access and operational strategies.

Our goal—every day—is to raise awareness of men’s health and to spark the conversations that will activate men to be proactive in their healthcare.

James Holloway

Vice President, Manufacturing and Supply

James Holloway joined Clarus Therapeutics in October 2019 as Vice President, Manufacturing and Supply with extensive experience in pharmaceutical manufacturing operations. His background includes roles of increasing responsibility at DSM Pharmaceuticals, Cardinal Health, Pfizer and Boehringer Ingelheim. Prior to Clarus Therapeutics, he led the research and development project management office of the Infection Prevention franchise of CareFusion (now BD Medical), where he increased revenue and improved on-time delivery. Mr. Holloway has launched more than 55 drugs and biologic products.

We strive to make a difference in men’s health by focusing on developing a high-quality, safe, and effective TRT product.

Gregory Fox

Vice President, Market Access

Gregory Fox, a 23-year veteran of the pharmaceutical industry, has been a contributor to many sides of the business including sales, sales leadership, sales training, market access and trade. He joined Clarus Therapeutics in March 2021 as Vice President of Market Access. Prior to Clarus Therapeutics, Mr. Fox held leadership roles at SK Life Science as Executive Director of Market Access and Ironshore Pharmaceuticals and Development as Vice President of Corporate Accounts. Mr. Fox also spent the first 19 years of his pharmaceutical career with UCB and has successfully led market access teams of varying sizes and scopes for the last 11 years.

Creating access to medicines for patients is one of the most important jobs in pharma and is the reason for my passion in this industry.

Steve Stark

Vice President, Commercial Analytics and Operations

Steve Stark brings over 20 years of experience within commercial analytics and operations in the biopharmaceutical industry. Prior to joining Clarus Therapeutics, Mr. Stark held strategic and leadership roles at ZS Associates and Abbott/AbbVie. Most recently, he was Senior Director of Business Insights at Lundbeck. In that role, he led market research, brand and payer analytics, forecasting and commercial assessment in delivering integrated insights to inform brand decisions.

At Clarus Therapeutics, we are committed to bringing innovative products to the market to improve men’s health. I’m proud to be part of an organization with such a meaningful mission.

Robert E. Dudley

Chairman, Chief Executive Officer and President, Clarus Therapeutics, Inc.

Robert E. Dudley, Ph.D., has devoted his career to developing products that revolutionize healthcare for men. As the co-inventor of multiple formulations of testosterone replacement therapies, he is a leading voice in hypogonadism and men’s health.

Driven by a mission to help men overcome the symptoms of hypogonadism, Dr. Dudley established Clarus Therapeutics, Inc. in 2004 and has served as Chief Executive Officer, President and Chairman of the Board of Directors since its founding. Prior to founding Clarus Therapeutics, Dr. Dudley served as the President, Chief Executive Officer and Director of Anagen Therapeutics. He also held senior executive positions at Unimed Pharmaceuticals, including President and CEO. Dr. Dudley has more than 30 years of experience in the testosterone replacement therapy field. Most notably, he led the discovery, development, regulatory approval and launch of AndroGel 1%, the first testosterone gel product, which became the market leader.

James E. Thomas

Managing Partner, Thomas, McNerney & Partners

James Thomas is a co-founder of Thomas, McNerney & Partners and has been investing in healthcare companies since 1992. Mr. Thomas previously headed Warburg Pincus LLC’s medical technology private equity practice, where he had responsibility for investments in biotechnology, pharmaceutical, medical device and diagnostic companies. Prior to joining Warburg, Mr. Thomas was a Vice President at Goldman Sachs International in London. He is currently a board member of CAS Medical Systems, Inc. (CASM), Clarus Therapeutics, Inc. and Keystone Dental, Inc.

Alex Zisson

Advisor, Thomas, McNerney & Partners

Alex Zisson serves on the board of directors for Clarus Therapeutics and Keystone Dental. He served as a Managing Director at H.I.G. BioHealth Partners before joining Thomas, McNerney & Partners. Mr. Zisson is the co-chair of the Business Advisory Council of the Children’s Tumor Foundation, an advisor for the Partnership Fund of NYC, which manages a bioaccelarator to advance local healthcare research, and is on the Life Sciences Council for Springboard Enterprises, a group that assists women entrepreneurs.

Bruce C. Robertson

Managing Director, H.I.G. BioHealth Partners

Bruce C. Robertson, Ph.D. serves as a Managing Director at H.I.G. BioHealth Partners, the dedicated healthcare affiliate of H.I.G. Capital, the leading private equity firm in the lower middle market, with $21 billion under management. He previously served as a Managing Director at Toucan Capital, a healthcare-focused venture capital firm. Dr. Robertson also serves on the board of directors of a number of private companies and organizations, including Iconic Therapeutics, CardioFocus, Inc., Apollo Endosurgery, and RxSight.

Mengjiao Jiang

Partner, C-Bridge Capital Partners LLC

Mengjiao Jiang is Partner of C-Bridge Capital Partners LLC, a China-based investment management firm focused on healthcare investments, which she co-founded. Prior to that, Ms. Jiang served as Chief Operating Officer and Director in the Principal Investments Group of Far East Horizon Ltd., a leasing company in China. Previously, she was Managing Director at the Shanghai-based investment manager, ARC China, where she established its China operations.

Elizabeth A. Cermak

Director, SteadyMed Therapeutics

Elizabeth A. Cermak is a Board Member for SteadyMed Therapeutics, where she also Chairs the Compensation Committee. Most recently, Ms. Cermak was Executive Vice President, Chief Commercial Officer and member of the Executive Committee of POZEN, Inc. She served as the Worldwide Vice President of Global Marketing for Personal Products, a segment of the Johnson & Johnson Consumer Health Care business, and also served as the Vice President of the Women’s Healthcare RX Franchise for Ortho-McNeil Pharmaceutical.

Mark A. Prygocki, Sr.

Executive Director, Member, Board of Directors and Chairman, Audit Committee of the Board of Directors, Clarus Therapeutics, Inc.

Mark A. Prygocki is currently a Member of the Board of Directors and serves as Chairman of the Audit Committee and Member, Nominating and Compensation Committees of Verrica Pharmaceuticals. Mr. Prygocki is the former CEO, President and Director of Illustris Pharmaceuticals, Inc., a privately held biodevelopment company and past President of Medicis Pharmaceutical Corporation. A pharmaceutical industry leader with over 25 years of experience, Mr. Prygocki specializes in corporate strategy and operational efficiency. He also serves on the board of Whispering Hope Ranch Foundation, a non-profit organization that assists children with special needs.

Thomas McNerny Partners

Thomas, McNerney & Partners is a health care venture firm that invests in life science and medical technology companies at all stages of development.

HIG biohealth Partners

H.I.G. BioHealth Partners invests in a broad range of healthcare companies across multiple sectors and stages of development with extensive and diverse experience in big pharma, small biotech, medical devices, diagnostics, basic science, clinical research, and technology transfer.

CBC Group

CBC Group is a dedicated private equity firm, focused on growth and late stage investment opportunities. CBC’s current portfolio includes China’s leading players in pharmaceuticals, medical devices, diagnostics, and healthcare services.

Pavilion Capital Partners

Pavilion Capital Partners is a growth-stage venture investor that provides capital and strategic support to fast growing companies in the United States and Asia.

BVCF Management, LTD.

Founded in 2005 by Dr. Zhi Yang, BVCF Management originally focused on life sciences and healthcare in China. In the past decade, BVCF has invested in nearly 30 companies spanning across both the US and China and covering a wide spectrum of highly promising fields, including healthcare services, innovative biologics, in-vitro diagnostics, high value medical equipment and consumables, and medical big data and mobile medicine.